Obermatt
See Similar Stocks →

Flags

Financial distress

Biodesix

NMQ:BDSX · US09075X2071
Health Care Providers & ServicesSmall

360

50
Profit price70
Owner Earnings Yield1
Dividend Yield1
Price/Sales60
EV / Gross Profit77
Price/Book95
Return on Capital6
Cash Return on Capital6
Return on Equity1
EBIT Margin10
Gross Profitability99
Accruals64
Owner Earnings Margin8
Sales growth80
Profit growth29
Reinvestment100
Price momentum92
Debt load5
Refinancing65
Debt Payback1
Liquidity33
Analyst ratings100
Opinion Changes50
Price Target Upside94
Market mood45
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Biodesix clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2005
Employees316
Websitebiodesix.com
ISINUS09075X2071
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
PulmonologyHealth DiagnosticsGeneticsArtificial IntelligenceRespiratoryOncologyBiotechnologyHealth CareScience and Engineering

Description

Biodesix, Inc. (‘Biodesix’) operates as a diagnostic solutions company. The company derives its revenue from two sources: Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing services for healthcare providers…

Analysis

Weak and unloved

Biodesix, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
80
2026

All-time high

80

Jun 2026

All-time low

28

Mar 2026

Average rank

54

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
60
—
—
—
Price/Earnings
—
—
—
—
Price/Book
95
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
67
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Biodesix with its peers
Guardant Health
NSQ:GH
14
CountryUSA
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →
Veracyte
NMQ:VCYT
80
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
GeneDx
NSQ:WGS
6
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Fulgent Genetics
NMQ:FLGT
4
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
LifeStance Health
NSQ:LFST
80
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Castle Biosciences
NMQ:CSTL
10
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →